BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 346 found
  Current Search:  glioblastoma: 346     

HTML
100%
Study identifies biomarker that safely monitors tumor response to new brain cancer treatment
The finding, reported in the July 1 issue of Clinical Cancer Research, paves the way for a Phase 1 clinical trial expected to begin in late 2009.

The gene therapy is a two-pronged strategy devised by scientists at the Cedars-Sinai Board of...

Innovations Report:  Jul 4 2009 6:48PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Presents Positive Results For LB-1.2 Trial
LB-1.2, is shown to have enhanced effectiveness of standard cancer chemotherapy in mouse models of human cancers National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) and National Institutes...
Pharmaceutical Business Review:  Jul 4 2009 2:43PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherap
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Chemotherapy In Animal Models Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical...
MediLexicon:  Jul 4 2009 7:50AM
Matching: glioblastoma
Find similar documents
HTML
100%
Novel Gene Therapy for Brain Tumor Nears Clinical Trial
THURSDAY, July 2 (HealthDay News) -- A novel gene therapy for glioblastoma multiforme utilizing a combination of adenoviral vectors and the drug ganciclovir (GCV) is nearing clinical trial with the discovery of a biomarker to gauge...
Modern Medicine:  Jul 3 2009 8:12AM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherap
Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte...
Medical News Today:  Jul 3 2009 11:31AM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
Lixte Biotechnology Holdings announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel...
Kait 8:  Jul 3 2009 4:30AM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National...
KSLA:  Jul 3 2009 12:30AM
Matching: glioblastoma
Find similar documents
HTML
100%
Study identifies biomarker that safely monitors tumor response to new brain cancer treatment
Gene therapy technique developed in animal model by Cedars-Sinai research team uses immune cells to attack glioblastoma multiforme 02 Jul 2009 - A specific biomarker, a protein released by dying tumor cells, has been identified as an...
Bionity.com:  Jul 2 2009 11:03AM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Staten Island Live:  Jul 2 2009 7:52PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National...
KLFY:  Jul 2 2009 7:15PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
Lixte Biotechnology Holdings E-Mail Print Reprint or license Text Size: tool name tool goes here EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators...
Sun Herald:  Jul 2 2009 3:55PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the...
KOTA Territory News:  Jul 2 2009 3:50PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
Companies mentioned in this article: Lixte Biotechnology Holdings EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of...
Freshnews.com:  Jul 2 2009 3:05PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
John S.

Kovach, President and CEO of Lixte, said 'LB-1.2 exerts anti-cancer activity directly on the cancer cell and, more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs.

Montana's News Station:  Jul 2 2009 2:38PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Pittsburgh Business Times:  Jul 2 2009 1:40PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI),...
Houston Chronicle:  Jul 2 2009 1:39PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT)...
Reuters:  Jul 2 2009 1:38PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Cincinnati Business Journal:  Jul 2 2009 1:38PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Birmingham Business Journal:  Jul 2 2009 1:35PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and...
San Antonio Business Journal:  Jul 2 2009 1:34PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Baltimore Business Journal:  Jul 2 2009 1:28PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the
Lixte Biotechnology Holdings Inc (LIXT) Stock Quote, Chart, News, Add to Watchlist EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the...
PR Newswire via MSN Money:  Jul 2 2009 1:26PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
Business First of Buffalo:  Jul 2 2009 1:26PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer...
St Louis Business Journal:  Jul 2 2009 1:24PM
Matching: glioblastoma
Find similar documents
HTML
100%
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherap
EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT - News) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National...
Yahoo! Canada:  Jul 2 2009 1:23PM
Matching: glioblastoma
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.